BACKGROUND: Cigarette smoking and other forms of tobacco use are the leading cause of preventable mortality in the world. A better understanding of the etiology of nicotine addiction may help to increase the success rate of cessation and to decrease the massive morbidity and mortality associated with smoking. METHODS: To identify genetic polymorphisms that contribute to nicotine dependence, our group undertook a genetic association study including three enzyme families that potentially influence nicotine metabolism: cytochrome P450 enzymes, flavin monooxygenases (FMOs), and UDP-glucuronosyl transferases. RESULTS: Several polymorphisms in FMO1 showed association in a discovery sample, and were tested in an independent replication sample. One polymorphism, rs10912765, showed an association that remained significant after Bonferroni correction (nominal P=0.0067, corrected P=0.0134). Several additional polymorphisms in linkage disequilibrium with this single nucleotide polymorphism also showed association. Subsequent in-vitro experiments characterized FMO1 as a more efficient catalyst of nicotine N-oxidation than FMO3. In adult humans, FMO1 is primarily expressed in the kidney and is likely to be a major contributor to the renal metabolism and clearance of therapeutic drugs. FMO1 is also expressed in the brain and could contribute to the nicotine concentration in this tissue. CONCLUSION: These findings suggest that polymorphisms in FMO1 are significant risk factors in the development of nicotine dependence and that the mechanism may involve variation in nicotine pharmacology.
BACKGROUND: Cigarette smoking and other forms of tobacco use are the leading cause of preventable mortality in the world. A better understanding of the etiology of nicotine addiction may help to increase the success rate of cessation and to decrease the massive morbidity and mortality associated with smoking. METHODS: To identify genetic polymorphisms that contribute to nicotine dependence, our group undertook a genetic association study including three enzyme families that potentially influence nicotine metabolism: cytochrome P450 enzymes, flavin monooxygenases (FMOs), and UDP-glucuronosyl transferases. RESULTS: Several polymorphisms in FMO1 showed association in a discovery sample, and were tested in an independent replication sample. One polymorphism, rs10912765, showed an association that remained significant after Bonferroni correction (nominal P=0.0067, corrected P=0.0134). Several additional polymorphisms in linkage disequilibrium with this single nucleotide polymorphism also showed association. Subsequent in-vitro experiments characterized FMO1 as a more efficient catalyst of nicotine N-oxidation than FMO3. In adult humans, FMO1 is primarily expressed in the kidney and is likely to be a major contributor to the renal metabolism and clearance of therapeutic drugs. FMO1 is also expressed in the brain and could contribute to the nicotine concentration in this tissue. CONCLUSION: These findings suggest that polymorphisms in FMO1 are significant risk factors in the development of nicotine dependence and that the mechanism may involve variation in nicotine pharmacology.
Authors: Jason Z Liu; Federica Tozzi; Dawn M Waterworth; Sreekumar G Pillai; Pierandrea Muglia; Lefkos Middleton; Wade Berrettini; Christopher W Knouff; Xin Yuan; Gérard Waeber; Peter Vollenweider; Martin Preisig; Nicholas J Wareham; Jing Hua Zhao; Ruth J F Loos; Inês Barroso; Kay-Tee Khaw; Scott Grundy; Philip Barter; Robert Mahley; Antero Kesaniemi; Ruth McPherson; John B Vincent; John Strauss; James L Kennedy; Anne Farmer; Peter McGuffin; Richard Day; Keith Matthews; Per Bakke; Amund Gulsvik; Susanne Lucae; Marcus Ising; Tanja Brueckl; Sonja Horstmann; H-Erich Wichmann; Rajesh Rawal; Norbert Dahmen; Claudia Lamina; Ozren Polasek; Lina Zgaga; Jennifer Huffman; Susan Campbell; Jaspal Kooner; John C Chambers; Mary Susan Burnett; Joseph M Devaney; Augusto D Pichard; Kenneth M Kent; Lowell Satler; Joseph M Lindsay; Ron Waksman; Stephen Epstein; James F Wilson; Sarah H Wild; Harry Campbell; Veronique Vitart; Muredach P Reilly; Mingyao Li; Liming Qu; Robert Wilensky; William Matthai; Hakon H Hakonarson; Daniel J Rader; Andre Franke; Michael Wittig; Arne Schäfer; Manuela Uda; Antonio Terracciano; Xiangjun Xiao; Fabio Busonero; Paul Scheet; David Schlessinger; David St Clair; Dan Rujescu; Gonçalo R Abecasis; Hans Jörgen Grabe; Alexander Teumer; Henry Völzke; Astrid Petersmann; Ulrich John; Igor Rudan; Caroline Hayward; Alan F Wright; Ivana Kolcic; Benjamin J Wright; John R Thompson; Anthony J Balmforth; Alistair S Hall; Nilesh J Samani; Carl A Anderson; Tariq Ahmad; Christopher G Mathew; Miles Parkes; Jack Satsangi; Mark Caulfield; Patricia B Munroe; Martin Farrall; Anna Dominiczak; Jane Worthington; Wendy Thomson; Steve Eyre; Anne Barton; Vincent Mooser; Clyde Francks; Jonathan Marchini Journal: Nat Genet Date: 2010-04-25 Impact factor: 38.330
Authors: E Billatos; A Faiz; Y Gesthalter; A LeClerc; Y O Alekseyev; X Xiao; G Liu; N H T Ten Hacken; I H Heijink; W Timens; C A Brandsma; D S Postma; M van den Berge; A Spira; M E Lenburg Journal: Physiol Genomics Date: 2018-06-22 Impact factor: 3.107
Authors: Meghan J Chenoweth; Andy Z X Zhu; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2014-03 Impact factor: 2.089
Authors: A M Teitelbaum; S E Murphy; G Akk; T B Baker; A Germann; L B von Weymarn; L J Bierut; A Goate; E D Kharasch; A J Bloom Journal: Pharmacogenomics J Date: 2017-03-14 Impact factor: 3.550
Authors: Yadira X Perez-Paramo; Gang Chen; Joseph H Ashmore; Christy J W Watson; Shamema Nasrin; Jennifer Adams-Haduch; Renwei Wang; Yu-Tang Gao; Woon-Puay Koh; Jian-Min Yuan; Philip Lazarus Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-31 Impact factor: 4.254
Authors: Oscar Harari; Jen-Chyong Wang; Kathleen Bucholz; Howard J Edenberg; Andrew Heath; Nicholas G Martin; Michele L Pergadia; Grant Montgomery; Andrew Schrage; Laura J Bierut; Pamela F Madden; Alison M Goate Journal: PLoS One Date: 2012-12-05 Impact factor: 3.240